Skip to main content

Table 5 Relative risk of second primary cancer by type of first primary cancer and follow-up interval, Queensland, 1982-2006

From: The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study

 

Follow-up interval

 

2 months to less than 1 year

1 year to less than 5 years

5 years to less than 10 years

10 years or longer

First primary cancer

Obs.

SIR

(95% CI)

Obs.

SIR

(95% CI)

Obs.

SIR

(95% CI)

Obs.

SIR

(95% CI)

   Head and neck

164

1.67

(1.42-1.95)

731

2.00

(1.86-2.15)

651

2.10

(1.94-2.26)

443

1.89

(1.72-2.08)

   Oesophagus

22

1.22

(0.77-1.85)

42

1.31

(0.95-1.77)

32

1.76

(1.20-2.48)

9

1.11

(0.51-2.10)

   Stomach

36

0.97

(0.68-1.35)

75

0.95

(0.74-1.18)

55

1.04

(0.78-1.35)

40

0.99

(0.71-1.35)

   Colorectal

310

1.03

(0.92-1.16)

1,131

1.07

(1.01-1.13)

912

1.11

(1.04-1.18)

693

1.14

(1.06-1.23)

   Pancreas

14

0.74

(0.40-1.24)

20

1.01

(0.62-1.57)

15

0.99

(0.55-1.64)

--

--

   Lung

147

1.06

(0.89-1.24)

312

1.46

(1.30-1.63)

183

1.71

(1.47-1.98)

87

1.35

(1.08-1.67)

   Melanoma

458

2.15

(1.95-2.35)

1,798

1.92

(1.84-2.02)

1,553

1.80

(1.71-1.89)

1,283

1.63

(1.55-1.73)

   Breast - female

194

1.02

(0.88-1.18)

1,020

1.25

(1.17-1.33)

1,019

1.44

(1.35-1.53)

729

1.36

(1.26-1.46)

   Cervix

33

2.13

(1.46-2.99)

89

1.46

(1.18-1.80)

89

1.43

(1.15-1.76)

89

1.09

(0.87-1.34)

   Uterus

29

1.03

(0.69-1.48)

134

1.15

(0.96-1.36)

147

1.36

(1.15-1.60)

99

1.00

(0.81-1.21)

   Ovary

22

1.22

(0.77-1.85)

54

1.04

(0.78-1.35)

46

1.18

(0.86-1.57)

42

1.11

(0.80-1.50)

   Prostate

344

0.81

(0.73-0.90)

1,368

0.84

(0.80-0.89)

988

0.88

(0.82-0.93)

306

0.66

(0.59-0.74)

   Kidney

115

2.45

(2.02-2.94)

254

1.57

(1.38-1.77)

177

1.42

(1.22-1.65)

109

1.35

(1.11-1.63)

   Bladder

249

2.40

(2.11-2.72)

668

1.73

(1.61-1.87)

477

1.61

(1.47-1.76)

286

1.39

(1.23-1.56)

   Brain & CNS

6

0.60

(0.22-1.31)

12

0.77

(0.40-1.34)

18

1.44

(0.85-2.28)

14

1.28

(0.70-2.15)

   Thyroid

18

1.65

(0.98-2.61)

78

1.53

(1.21-1.91)

63

1.21

(0.93-1.55)

56

1.16

(0.87-1.50)

   Non-Hodgkin lymphoma

74

1.23

(0.97-1.55)

262

1.31

(1.16-1.48)

209

1.46

(1.27-1.67)

144

1.49

(1.26-1.76)

   Lymphoid leukaemia

52

1.82

(1.36-2.39)

156

1.40

(1.19-1.64)

143

1.89

(1.59-2.23)

71

1.78

(1.37-2.22)

   Myeloid leukaemia

27

1.59

(1.05-2.31)

57

1.44

(1.09-1.87)

28

1.40

(0.93-2.03)

13

1.41

(0.75-2.41)

   Myeloma/PCT

18

0.76

(0.45-1.21)

68

1.02

(0.79-1.29)

36

1.26

(0.88-1.74)

12

1.12

(0.58-1.95)

   Other

179

1.22

(1.05-1.42)

595

1.35

(1.25-1.47)

447

1.36

(1.24-1.49)

332

1.33

(1.19-1.48)

   All cancers combined

2,511

1.32

(1.27-1.37)

8,924

1.33

(1.31-1.36)

7,286

1.39

(1.35-1.42)

4,859

1.28

(1.24-1.31)

  1. Obs. = Observed number of second primary cancers; SIR = standardised incidence ratio; CI = confidence interval; CNS = central nervous system; PCT = plasma cell tumours. SIRs shown in normal bold font indicate significantly increased risk; SIRs shown in bold italics indicate significantly decreased risk. SIRs for pancreatic cancer for 5 years to less than 10 years after first diagnosis and 10 years or longer after first diagnosis have been combined due to less than 5 observed cases 10 years or longer after first diagnosis.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us